Cipher Pharmaceuticals Future Growth

Future criteria checks 2/6

Cipher Pharmaceuticals is forecast to grow earnings and revenue by 10% and 17.4% per annum respectively. EPS is expected to grow by 9.5% per annum. Return on equity is forecast to be 13.5% in 3 years.

Key information

10.0%

Earnings growth rate

9.5%

EPS growth rate

Pharmaceuticals earnings growth	65.1%
Revenue growth rate	17.4%
Future return on equity	13.5%
Analyst coverage	Low
Last updated	11 Dec 2024

Recent future growth updates

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

Recent updates

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Dec 13

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Nov 14

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Nov 12

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Mar 20

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Jan 26

Earnings and Revenue Growth Forecasts

TSX:CPH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	54	19	N/A	25	2
12/31/2025	50	18	N/A	22	3
12/31/2024	34	12	N/A	17	3
9/30/2024	26	16	-67	13	N/A
6/30/2024	22	23	17	17	N/A
3/31/2024	22	23	14	14	N/A
12/31/2023	21	20	16	16	N/A
9/30/2023	21	32	15	15	N/A
6/30/2023	20	28	13	13	N/A
3/31/2023	20	27	13	13	N/A
12/31/2022	21	27	11	11	N/A
9/30/2022	22	10	15	15	N/A
6/30/2022	21	8	11	11	N/A
3/31/2022	22	9	11	11	N/A
12/31/2021	22	8	14	14	N/A
9/30/2021	22	5	14	14	N/A
6/30/2021	23	6	12	12	N/A
3/31/2021	21	3	11	11	N/A
12/31/2020	22	4	11	12	N/A
9/30/2020	21	7	7	7	N/A
6/30/2020	22	3	10	11	N/A
3/31/2020	23	4	11	12	N/A
12/31/2019	22	3	7	8	N/A
9/30/2019	23	-1	6	8	N/A
6/30/2019	22	2	4	6	N/A
3/31/2019	23	3	0	2	N/A
12/31/2018	23	1	1	8	N/A
9/30/2018	28	6	7	13	N/A
6/30/2018	34	9	N/A	18	N/A
3/31/2018	37	11	N/A	19	N/A
12/31/2017	40	11	N/A	13	N/A
9/30/2017	34	7	N/A	11	N/A
6/30/2017	32	5	N/A	9	N/A
3/31/2017	31	1	N/A	10	N/A
12/31/2016	30	4	N/A	11	N/A
9/30/2016	33	6	N/A	8	N/A
6/30/2016	34	2	N/A	7	N/A
3/31/2016	34	1	N/A	7	N/A
12/31/2015	34	2	N/A	8	N/A
9/30/2015	32	3	N/A	12	N/A
6/30/2015	30	13	N/A	16	N/A
3/31/2015	30	18	N/A	19	N/A
12/31/2014	29	19	N/A	25	N/A
9/30/2014	33	31	N/A	23	N/A
6/30/2014	32	27	N/A	18	N/A
3/31/2014	29	25	N/A	15	N/A
12/31/2013	25	24	N/A	7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPH's forecast earnings growth (10% per year) is above the savings rate (2.3%).

Earnings vs Market: CPH's earnings (10% per year) are forecast to grow slower than the Canadian market (15.5% per year).

High Growth Earnings: CPH's earnings are forecast to grow, but not significantly.

Revenue vs Market: CPH's revenue (17.4% per year) is forecast to grow faster than the Canadian market (7.1% per year).

High Growth Revenue: CPH's revenue (17.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CPH's Return on Equity is forecast to be low in 3 years time (13.5%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 00:09
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cipher Pharmaceuticals Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Douglas Loe	Byron Capital Markets
Prakash Gowd	CIBC Capital Markets
David Novak	Cormark Securities Inc.

Cipher Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 7.4% to CA$17.37

Consensus EPS estimates increase by 10%

Consensus revenue estimates increase by 37%

Consensus EPS estimates increase by 53%

Recent updates

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Investor sentiment deteriorates as stock falls 15%

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 7.4% to CA$17.37

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus revenue estimates increase by 37%

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Investor sentiment improves as stock rises 27%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 53%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock.

Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold CA$61k worth of stock

Price target increased to CA$4.13

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

First quarter 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to CA$3.30

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)

Investor sentiment improved over the past week

Consensus EPS estimates increase to US$0.31

Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)

Price target increased to CA$1.82

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$21.5m